Table 1:
Baseline Characteristics for the Intention to Treat Population
| Characteristic | Azithromycin (N=249) |
Placebo (N=250) |
All Subjects (N=499) |
|---|---|---|---|
| Age in years, mean (standard deviation) | 52·8 (15·9) | 51·7 (15·0) | 52·2 (15·5) |
| Sex, n (%) | |||
| Male | 169 (68) | 154 (62) | 323 (65) |
| Female | 80 (32) | 96 (38) | 176 (35) |
| Race, n (%) | |||
| White | 81 (33) | 89 (36) | 170 (34) |
| Black or African American | 159 (64) | 146 (58) | 305 (61) |
| Asian | 4 (2) | 1 (<1) | 5 (1) |
| American Indian or Alaska Native | - | 3 (1) | 3 (<1) |
| Native Hawaiian or Other Pacific Islander | - | 1 (<1) | 1 (<1) |
| Multiracial | 2 (<1) | 8 (3) | 10 (2) |
| Unknown | 3 (1) | 2 (<1) | 5 (1) |
| Ethnicity, n (%) | |||
| Not Hispanic or Latino | 228 (92) | 233 (93) | 461 (92) |
| Hispanic or Latino | 17 (7) | 16 (6) | 33 (7) |
| Unknown | 4 (2) | 1 (<1) | 5 (1) |
| Pre-existing medical disorders, n (%)1 | |||
| Any | 225 (90) | 230 (92) | 455 (91) |
| Vascular | 136 (55) | 112 (45) | 248 (50) |
| Metabolic | 118 (47) | 108 (43) | 226 (45) |
| Respiratory | 102 (41) | 116 (46) | 218 (44) |
| Psychiatric | 66 (27) | 69 (28) | 135 (27) |
| Gastrointestinal | 54 (22) | 64 (26) | 118 (24) |
| Musculoskeletal/connective tissue | 58 (23) | 56 (22) | 114 (23) |
| Baseline LRTI Symptoms/Signs, n (%) | |||
| Chest Pain | 151 (61) | 157 (63) | 308 (62) |
| Cough | 243 (98) | 245 (98) | 488 (98) |
| Difficulty Breathing | 177 (71) | 182 (73) | 359 (72) |
| Fever | 117 (47) | 115 (46) | 232 (46) |
| Sputum Production | 219 (88) | 205 (82) | 424 (85) |
1
Only pre-existing condition categories with >15% prevalence are listed.